MCR-1-dependent lipid remodelling compromises the viability of Gram-negative bacteria

Emerg Microbes Infect. 2022 Dec;11(1):1236-1249. doi: 10.1080/22221751.2022.2065934.

Abstract

The global dissemination of the mobilized colistin resistance gene, mcr-1, threatens human health. Recent studies by our group and others have shown that the withdrawal of colistin as a feed additive dramatically reduced the prevalence of mcr-1. Although it is accepted that the rapid reduction in mcr-1 prevalence may have resulted, to some extent, from the toxic effects of MCR-1, the detailed mechanism remains unclear. Here, we found that MCR-1 damaged the outer membrane (OM) permeability in Escherichia coli and Klebsiella pneumonia and that this event was associated with MCR-1-mediated cell shrinkage and death during the stationary phase. Notably, the capacity of MCR-1-expressing cells for recovery from the stationary phase under improved conditions was reduced in a time-dependent manner. We also showed that mutations in the potential lipid-A-binding pocket of MCR-1, but not in the catalytic domain, restored OM permeability and cell viability. During the stationary phase, PbgA, a sensor of periplasmic lipid-A and LpxC production that performed the first step in lipid-A synthesis, was reduced after MCR-1 expression, suggesting that MCR-1 disrupted lipid homeostasis. Consistent with this, the overexpression of LpxC completely reversed the MCR-1-induced OM permeability defect. We propose that MCR-1 causes lipid remodelling that results in an OM permeability defect, thus compromising the viability of Gram-negative bacteria. These findings extended our understanding of the effect of MCR-1 on bacterial physiology and provided a potential strategy for eliminating drug-resistant bacteria.

Keywords: MCR-1; colistin; lipid homeostasis; outer membrane (OM) permeability; viability.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Colistin* / pharmacology
  • Drug Resistance, Bacterial / genetics
  • Escherichia coli
  • Escherichia coli Proteins* / genetics
  • Escherichia coli Proteins* / metabolism
  • Gram-Negative Bacteria* / drug effects
  • Gram-Negative Bacteria* / genetics
  • Gram-Negative Bacteria* / metabolism
  • Humans
  • Plasmids

Substances

  • Anti-Bacterial Agents
  • Escherichia coli Proteins
  • MCR-1 protein, E coli
  • Colistin

Grants and funding

This work has been supported by grants from National Natural Science Foundation of China [grant number 81830103], [grant number 82061128001], [grant number 82002173], Project of high-level health teams of Zhuhai at 2018 (The Innovation Team for Antimicrobial Resistance and Clinical Infection), 111 Project [grant number B12003], and Open project of Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education [grant number 2020kfkt04], [grant number 2020kfkt07].